167 related articles for article (PubMed ID: 37908267)
1. Reduction of Proteinuria in a Patient With Primary Aldosteronism by Angiotensin II Receptor Blocker Administration.
Rikitake J; Ashida K; Miura M; Nomura M
JCEM Case Rep; 2023 Jan; 1(1):luac021. PubMed ID: 37908267
[TBL] [Abstract][Full Text] [Related]
2. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Tezuka Y; Turcu AF
Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
[TBL] [Abstract][Full Text] [Related]
4. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
5. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
6. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
9. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
11. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
Morimoto S; Ichihara A
Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
[TBL] [Abstract][Full Text] [Related]
12. Some considerations about evolution of idiopathic primary aldosteronism.
Armanini D; Fiore C
J Endocrinol Invest; 2009 Jul; 32(7):623-5. PubMed ID: 19893360
[TBL] [Abstract][Full Text] [Related]
13. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
15. Continuum of Renin-Independent Aldosteronism in Normotension.
Baudrand R; Guarda FJ; Fardella C; Hundemer G; Brown J; Williams G; Vaidya A
Hypertension; 2017 May; 69(5):950-956. PubMed ID: 28289182
[TBL] [Abstract][Full Text] [Related]
16. Activation of aldosterone secretion in primary aldosteronism.
Spark RF; Dale SL; Kahn PC; Melby JC
J Clin Invest; 1969 Jan; 48(1):96-104. PubMed ID: 4303791
[TBL] [Abstract][Full Text] [Related]
17. Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Zacharieva S; Atanassova I; Natchev E; Orbetzova M; Tzingilev D
Methods Find Exp Clin Pharmacol; 2001 Apr; 23(3):153-6. PubMed ID: 11523316
[TBL] [Abstract][Full Text] [Related]
18. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
Shibata H; Itoh H
Am J Hypertens; 2012 May; 25(5):514-23. PubMed ID: 22258336
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
